Walk into any traditional ayahuasca ceremony in the Amazon and you'll notice something the modern clinical model still struggles to replicate: nobody's drinking alone. There's a circle. A shared darkness. A song that holds everyone in it. For thousands of years, this is what plant medicine has looked like — collective, relational, sung into being by people who showed up together.

Now, somewhat ironically, Western researchers are catching up. Group-based psychedelic therapy is having a moment in clinical journals, in psychiatric conferences, and in the strategy decks of companies thinking about how to actually deliver psychedelics to the millions of people who might benefit. If you're researching a retreat right now — weighing whether to sit in a circle of strangers or pay for a one-on-one session — this shift matters more than it might seem.

Why Group Models Are Suddenly the Conversation

The reason is partly practical and partly philosophical. Practically, there simply aren't enough trained facilitators to deliver one-on-one psychedelic therapy at any meaningful scale. If psilocybin gets approved for treatment-resistant depression and even a fraction of eligible patients show interest, the math doesn't work. You can't 1:1 your way out of a mental health crisis affecting tens of millions.

Philosophically, though, something deeper is going on. Researchers like Dr. Leor Roseman have been exploring what he calls communitas — that strange, electric sense of belonging that can arise when people take psychedelics together. His work suggests the collective container isn't just a logistical workaround. It might be doing something the solo experience can't. Loneliness, after all, is now considered a public health emergency in much of the Western world. If a chunk of our psychological suffering comes from disconnection, then maybe healing it requires reconnection — not just more introspection on a therapist's couch.

This isn't a new idea. In the mid-twentieth century, before the legal shutters came down, clinicians were already running LSD groups for alcohol use disorder and various neurotic conditions. The plant-medicine traditions of the Amazon, the Mazatec mushroom velada, the Native American Church's peyote meetings — all of these are group rituals. The lone-seeker-in-a-recliner model is actually the historical anomaly.

What a Group Psychedelic Container Actually Looks Like

If you've never been in one, here's roughly what to expect. A group ceremony — whether ayahuasca in Peru, psilocybin in a legal Dutch retreat, or a clinical trial format — typically gathers somewhere between six and twenty participants. You arrive a day or two early. There's preparation: conversations about intention, a medical screening, sometimes a dietary protocol. You meet the people you'll be journeying with.

The dosing itself happens in a shared space. In traditional ayahuasca work, that's often a maloca — a thatched-roof ceremonial structure — with mats arranged around the perimeter and curanderos working their icaros (the songs sung over each participant). In a clinical psilocybin group, it's usually a quieter, more living-room-feeling space, eye masks on, curated music piped through speakers, two or three facilitators circulating. Either way, you go inward. Mostly. But the presence of others — their breathing, their occasional crying, the song carrying the whole room — becomes part of the journey.

The integration days afterward are where the group dimension really earns its keep. Sitting in a circle with five other people who just had a similar experience, hearing what came up for them, watching someone else articulate something you couldn't quite name in yourself — that's a kind of mirror that solo integration can't easily provide. People often describe leaving these retreats with a small network of others who understand what they saw. That's not nothing.

Is Group Plant Medicine Right for You? A Few Honest Questions

Group containers aren't for everyone, and any facilitator worth their salt will tell you so. Here are the questions actually worth sitting with before you book:

• How do you handle being witnessed in vulnerable states? If the thought of crying — or worse, purging — in front of strangers makes your stomach drop, that's information. It doesn't necessarily mean don't go. Plenty of people find the witnessing itself is the medicine. But know yourself.
• Are you working with trauma that has a strong interpersonal component? Some people find groups deeply healing for relational wounds. Others find the group dynamic too activating to settle into the experience. A pre-retreat conversation with a therapist who understands psychedelics can help you figure out which camp you're likely in.
• How important is bespoke attention? In a one-on-one container, the facilitator's entire focus is on you. In a group, attention is shared. Good retreats keep favorable ratios — typically one facilitator per three or four participants for ayahuasca work — but it's still divided.
• Are you using plant medicine to address active addiction? Group work can be extraordinary for addiction recovery — there's a reason AA and similar models lean on the collective. But the prep, screening, and aftercare matter enormously. Ibogaine and ayahuasca have both shown promise here, but the wrong container can do more harm than good.

Master Plants, Modern Medicine, and the Question of Scale

One of the more interesting tensions in the current psychedelic moment is between the indigenous understanding of ayahuasca, San Pedro, peyote, and tobacco as master plants — sentient teachers with whom one builds relationship over years — and the Western drive to standardise, dose, and scale these substances into clinical products. Group ceremonies, when held in traditional or traditionally-informed settings, preserve more of that relational quality. The plant is treated as a teacher in the room, not a compound being delivered.

That distinction matters when you're choosing a retreat. A clinical psilocybin group in Oregon and an ayahuasca circle led by a Shipibo maestra in the Peruvian Amazon are both group psychedelic experiences. But they're aiming at different things, drawing on different lineages, and asking different things of the participant. Neither is better in some absolute sense. They're just different doors into different rooms.

If you're drawn toward the traditional end of the spectrum, look for retreats that work with established lineages — Shipibo, Quechua, Huachuma traditions in South America, or the Bwiti tradition for ibogaine in Gabon. Ask who the facilitators trained with, for how long, and what their relationship to the source community looks like. If you're drawn toward the clinical end, look for facilitators with formal psychotherapeutic training, transparent safety protocols, and a clear preparation and integration arc.

The Practical Stuff: Cost, Length, and Red Flags

Group retreats are generally — though not always — more affordable than fully bespoke one-on-one work. A reputable week-long ayahuasca retreat in Peru tends to run somewhere between $1,500 and $4,000, depending on accommodations, the number of ceremonies, and the lineage of the facilitators. Legal psilocybin retreats in the Netherlands, Jamaica, or Mexico typically land in a similar range. Ibogaine, because it requires medical supervision, runs higher — often $6,000 to $10,000 or more.

Red flags to actually watch for, in any group container:

1. No medical screening, or screening that feels perfunctory. A good retreat will ask detailed questions about medications, cardiovascular history, and family psychiatric history. If they don't, walk away.
2. Vague answers about facilitator training and lineage. A serious facilitator can tell you where they trained, with whom, for how long, and what their ongoing practice looks like.
3. No integration support beyond the retreat itself. The days and weeks after are where most of the work actually happens. If aftercare is an afterthought, the model is broken.
4. Promises of healing. Anyone guaranteeing outcomes is selling something. Good facilitators speak in possibilities, not certainties.
5. Group sizes that feel industrial. Twenty people per facilitator is not a ceremony, it's a tour.

What the Research Is Actually Showing

The evidence base for group psychedelic therapy is still thinner than for individual models, partly because most clinical trials have been built around 1:1 dosing for regulatory reasons. But what exists is encouraging. Studies on group psilocybin for demoralisation in long-term AIDS survivors, group MDMA work for veterans, and various ayahuasca outcomes research have shown comparable benefits to individual protocols, sometimes with the added dimension of sustained community after the experience ends.

The qualitative findings are perhaps more striking. Participants in group containers consistently report that the shared experience itself — the sense of journeying alongside others — was a core part of what made the work meaningful. Whether that translates into measurable clinical outcomes that beat individual therapy is still being studied. But for many people, the relational dimension isn't a side effect. It's the point.

If you're someone who's been quietly considering a retreat — whether for depression that won't lift, an addiction that hasn't responded to anything else, trauma that lives in your body, or just a sense that something in your life needs to crack open — group plant medicine is worth taking seriously. It won't be right for everyone. But the loneliness most of us carry around like a second skeleton might not heal in isolation. For readers who want to take this further, a thoughtfully curated range of group ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here.

Whatever container you choose, choose it carefully. Ask hard questions. Trust your gut about facilitators. And give yourself the integration time afterward — the medicine doesn't end when you leave the maloca.